



## **Compugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020**

HOLON, ISRAEL, April 23, 2020 — [Compugen Ltd.](#) (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2020 financial results on Wednesday, May 6, 2020 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-888-407-2553 from the U.S., or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen's website, located at the following [link](#). Following the live audio webcast, a replay will be available on the Company's website.

### **About Compugen**

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at [www.cgen.com](http://www.cgen.com).

### **Company contact:**

Elana Holzman

Director, Investor Relations and Corporate Communications

Compugen Ltd.

Email: [elanah@cgen.com](mailto:elanah@cgen.com)

Tel: +972 (3) 765-8124

**Investor Relations contact:**

Bob Yedid

LifeSci Advisors, LLC

Email: [bob@lifesciadvisors.com](mailto:bob@lifesciadvisors.com)

Tel: +1 (646) 597-6989

**Media contact:**

Josephine Belluardo, Ph.D.

LifeSci Communications

Email: [jo@lifescicomms.com](mailto:jo@lifescicomms.com)

Tel: +1 (646) 751-4361